A5082019829- Prostate Cancer Treatment and Research
- Cancer Immunotherapy and Biomarkers
- Cancer, Lipids, and Metabolism
- Hormonal and reproductive studies
- Renal cell carcinoma treatment
- Radiopharmaceutical Chemistry and Applications
- Lung Cancer Treatments and Mutations
- Pharmacogenetics and Drug Metabolism
- Multiple Myeloma Research and Treatments
- Cancer Genomics and Diagnostics
- Genetic factors in colorectal cancer
- Economic and Financial Impacts of Cancer
- Cancer Treatment and Pharmacology
- COVID-19 Clinical Research Studies
- Radiomics and Machine Learning in Medical Imaging
- Renal and related cancers
- Infection Control and Ventilation
- Lung Cancer Diagnosis and Treatment
- Pancreatic and Hepatic Oncology Research
- COVID-19 and healthcare impacts
- Lung Cancer Research Studies
- Advanced Breast Cancer Therapies
Université Paris Cité
2021-2024
Assistance Publique – Hôpitaux de Paris
2022-2024
Institut Gustave Roussy
2024
Hôpital Européen Georges-Pompidou
2021-2024
Institut Bergonié
2024
Hôpital Bichat-Claude-Bernard
2022-2023
Université Claude Bernard Lyon 1
2021-2023
Inserm
2021-2022
Institut Curie
2021
Hôpital Cochin
2018
Immune checkpoint inhibitors (ICI) have been approved for front-line therapy in metastatic renal cell carcinoma (mRCC). However, progressive disease often occurs and subsequent therapies are needed. ICI rechallenge may be an option, but there is a lack of data regarding efficacy prognostic factors. We assessed factors associated with better outcomes. Patients Methods. This ambispective multicenter study included 45 mRCC patients rechallenged nivolumab ± ipilimumab between 2014 2020. Primary...
Background: Immune checkpoint inhibitors (ICIs) have been a major advance in treating non-small-cell lung cancer (NSCLC). Programmed cell death protein-1/programmed death-ligand 1 blockade enhances immune function, mediating anti-tumor activity, yet causing immune-related adverse events (irAEs). We investigated the prognostic role of Grade 3–4 irAEs on overall survival (OS). Methods: This observational study recruited advanced NSCLC patients who received ICIs at Bichat-Claude Bernard...
Background: Androgen receptor signaling inhibitors (ARSis) abiraterone acetate (AA) plus prednisone and enzalutamide (Enza), are currently the most administered first-line treatments for metastatic castration-resistant prostate cancer (mCRPC). AA Enza have shown similar overall survival (OS) benefits there is no consensus upon best option mCRPC treatment. Volume of disease may represent a useful biomarker to predict response therapy in such patients. Objectives: In this study, we seek...
The CABASTY study showed that more frequent administration of a lower dose cabazitaxel (CBZ) reduced toxicity in older men with metastatic castration-resistant prostate cancer (mCRPC), without compromising efficacy. Here, we investigated the impact biweekly CBZ schedule on patient-reported pain and health-related quality life (HRQoL).
330 Background: Immune checkpoint inhibitors (ICIs) in combination with another ICI or an antiangiogenic targeted therapy have been approved for frontline metastatic renal cell carcinoma (mRCC). However, progression disease (PD) often occurs and subsequent therapies are needed. Rechallenge of may then be option, but there is a lack data regarding this strategy. Methods: This ambispective multicenter study included patients who received rechallenge Nivolumab (ICI-2) between January 2014...